Volume | 13,963 |
|
|||||
News | - | ||||||
Day High | 4.50 | Low High |
|||||
Day Low | 4.36 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | EGRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.50 | 4.36 | 4.50 | 4.55 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
187 | 13,963 | $ 4.44 | $ 62,057 | - | 4.10 - 30.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:30:17 | 200 | $ 4.45 | USD |
Eagle Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
59.09M | 12.99M | - | 316.61M | 35.64M | 2.74 | 1.66 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eagle Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EGRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.36 | 5.01 | 4.36 | 4.57 | 132,378 | 0.09 | 2.06% |
1 Month | 4.96 | 5.40 | 4.28 | 4.81 | 165,697 | -0.51 | -10.28% |
3 Months | 5.85 | 6.81 | 4.28 | 5.41 | 180,080 | -1.40 | -23.93% |
6 Months | 14.01 | 14.78 | 4.10 | 5.79 | 220,925 | -9.56 | -68.24% |
1 Year | 27.53 | 30.40 | 4.10 | 11.35 | 189,515 | -23.08 | -83.84% |
3 Years | 44.07 | 58.25 | 4.10 | 28.05 | 153,035 | -39.62 | -89.90% |
5 Years | 51.54 | 64.94 | 4.10 | 36.73 | 152,162 | -47.09 | -91.37% |
Eagle Pharmaceuticals Description
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. |